Cargando…

iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome

Alport syndrome (AS) is a hereditary glomerulonephritis caused by COL4A3, COL4A4 or COL4A5 gene mutations and characterized by abnormalities of glomerular basement membranes (GBMs). Due to a lack of curative treatments, the condition proceeds to end-stage renal disease even in adolescents. Hampering...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirayama, Ryuichiro, Toyohara, Kosuke, Watanabe, Kei, Otsuki, Takeya, Araoka, Toshikazu, Mae, Shin-Ichi, Horinouchi, Tomoko, Yamamura, Tomohiko, Okita, Keisuke, Hotta, Akitsu, Iijima, Kazumoto, Nozu, Kandai, Osafune, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539496/
https://www.ncbi.nlm.nih.gov/pubmed/37770589
http://dx.doi.org/10.1038/s42003-023-05203-4
_version_ 1785113511665336320
author Hirayama, Ryuichiro
Toyohara, Kosuke
Watanabe, Kei
Otsuki, Takeya
Araoka, Toshikazu
Mae, Shin-Ichi
Horinouchi, Tomoko
Yamamura, Tomohiko
Okita, Keisuke
Hotta, Akitsu
Iijima, Kazumoto
Nozu, Kandai
Osafune, Kenji
author_facet Hirayama, Ryuichiro
Toyohara, Kosuke
Watanabe, Kei
Otsuki, Takeya
Araoka, Toshikazu
Mae, Shin-Ichi
Horinouchi, Tomoko
Yamamura, Tomohiko
Okita, Keisuke
Hotta, Akitsu
Iijima, Kazumoto
Nozu, Kandai
Osafune, Kenji
author_sort Hirayama, Ryuichiro
collection PubMed
description Alport syndrome (AS) is a hereditary glomerulonephritis caused by COL4A3, COL4A4 or COL4A5 gene mutations and characterized by abnormalities of glomerular basement membranes (GBMs). Due to a lack of curative treatments, the condition proceeds to end-stage renal disease even in adolescents. Hampering drug discovery is the absence of effective in vitro methods for testing the restoration of normal GBMs. Here, we aimed to develop kidney organoid models from AS patient iPSCs for this purpose. We established iPSC-derived collagen α5(IV)-expressing kidney organoids and confirmed that kidney organoids from COL4A5 mutation-corrected iPSCs restore collagen α5(IV) protein expression. Importantly, our model recapitulates the differences in collagen composition between iPSC-derived kidney organoids from mild and severe AS cases. Furthermore, we demonstrate that a chemical chaperone, 4-phenyl butyric acid, has the potential to correct GBM abnormalities in kidney organoids showing mild AS phenotypes. This iPSC-derived kidney organoid model will contribute to drug discovery for AS.
format Online
Article
Text
id pubmed-10539496
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105394962023-09-30 iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome Hirayama, Ryuichiro Toyohara, Kosuke Watanabe, Kei Otsuki, Takeya Araoka, Toshikazu Mae, Shin-Ichi Horinouchi, Tomoko Yamamura, Tomohiko Okita, Keisuke Hotta, Akitsu Iijima, Kazumoto Nozu, Kandai Osafune, Kenji Commun Biol Article Alport syndrome (AS) is a hereditary glomerulonephritis caused by COL4A3, COL4A4 or COL4A5 gene mutations and characterized by abnormalities of glomerular basement membranes (GBMs). Due to a lack of curative treatments, the condition proceeds to end-stage renal disease even in adolescents. Hampering drug discovery is the absence of effective in vitro methods for testing the restoration of normal GBMs. Here, we aimed to develop kidney organoid models from AS patient iPSCs for this purpose. We established iPSC-derived collagen α5(IV)-expressing kidney organoids and confirmed that kidney organoids from COL4A5 mutation-corrected iPSCs restore collagen α5(IV) protein expression. Importantly, our model recapitulates the differences in collagen composition between iPSC-derived kidney organoids from mild and severe AS cases. Furthermore, we demonstrate that a chemical chaperone, 4-phenyl butyric acid, has the potential to correct GBM abnormalities in kidney organoids showing mild AS phenotypes. This iPSC-derived kidney organoid model will contribute to drug discovery for AS. Nature Publishing Group UK 2023-09-28 /pmc/articles/PMC10539496/ /pubmed/37770589 http://dx.doi.org/10.1038/s42003-023-05203-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hirayama, Ryuichiro
Toyohara, Kosuke
Watanabe, Kei
Otsuki, Takeya
Araoka, Toshikazu
Mae, Shin-Ichi
Horinouchi, Tomoko
Yamamura, Tomohiko
Okita, Keisuke
Hotta, Akitsu
Iijima, Kazumoto
Nozu, Kandai
Osafune, Kenji
iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
title iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
title_full iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
title_fullStr iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
title_full_unstemmed iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
title_short iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
title_sort ipsc-derived type iv collagen α5-expressing kidney organoids model alport syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539496/
https://www.ncbi.nlm.nih.gov/pubmed/37770589
http://dx.doi.org/10.1038/s42003-023-05203-4
work_keys_str_mv AT hirayamaryuichiro ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT toyoharakosuke ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT watanabekei ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT otsukitakeya ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT araokatoshikazu ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT maeshinichi ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT horinouchitomoko ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT yamamuratomohiko ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT okitakeisuke ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT hottaakitsu ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT iijimakazumoto ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT nozukandai ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome
AT osafunekenji ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome